Idorsia Ltd announced positive results from its Phase II study of daridorexant for children with insomnia disorder. Executives hosted a conference call on March 31, 2026, to review the findings, first revealed the previous day.
Key Study Highlights
The trial targets pediatric insomnia, including cases linked to neurodevelopmental disorders. Daridorexant remains investigational for this population and awaits regulatory approval in any market. Company leaders emphasized the drug’s potential while noting associated investment risks through forward-looking statements.
Executive Team Insights
Kevin Boss opened the discussion, stating, “We are here to discuss the positive results of the Phase II study of daridorexant for children with insomnia disorder.”
Presenters included Jean-Paul Clozel, Chairman of the Board and Interim CEO; Martine Clozel, Executive Vice President, Chief Scientific Officer, and Head of Research; and Alberto Gimona, Executive Vice President and Head of Global Clinical Development and Medical Affairs. They outlined the daridorexant program and detailed the study’s key outcomes.
Analyst Engagement
Analysts from H.C. Wainwright & Co., Octavian AG, and Kepler Cheuvreux joined for questions following the presentations. The session underscored Idorsia’s progress in addressing unmet needs in pediatric sleep disorders.
